
, Seok Soo Lee2
, Changseok Jeon3
, Tae Hee Won4, Sang-Wan Ryu5, JongHyun Baek6
1Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, USA
2Department of Thoracic and Cardiovascular Surgery, Changwon Hanmaeum Hospital, Changwon Korea
3Department of Thoracic and Cardiovascular Surgery, Incheon Sejong Hospital, Incheon, Korea
4Department of Thoracic and Cardiovascular Surgery, Ewha Womans University Seoul Hospital, Ewha Womans University School of Medicine, Seoul, Korea
5Department of Thoracic and Cardiovascular Surgery, International St. Mary’s Hospital, Incheon, Korea
6Department of Thoracic and Cardiovascular Surgery, Yeungnam University College of Medicine, Daegu, Korea
© 2026 Yeungnam University College of Medicine, Yeungnam University Institute of Medical Science
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Conflicts of interest
No potential conflict of interest relevant to this article was reported.
Funding
None.
Author contributions
Conceptualization: HS, THW, SWR, JB; Data curation: HS, SSL, CJ, THW, JB; Formal analysis: HS, CJ; Investigation, Project administration: HS; Methodology: HS, JB; Resources: HS, CJ, THW, SWR; Software, Visualization: HS, SSL; Supervision: JB; Writing-original draft: HS; Writing-review & editing: HS, JB.
M, male; F, female; OP, operation; PLT, platelet count; Hb, hemoglobin; Hct, hematocrit; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; CPB, cardiopulmonary bypass; ACC, aortic cross-clamp; ICU, intensive care unit; GW, general ward; AVR, aortic valve replacement; MVR, mitral valve replacement; IE, infective endocarditis; AV block, atrioventricular block; AscAoR, ascending aorta replacement; CABG, coronary artery bypass grafting; TVP, tricuspid valvuloplasty; CVA, cerebrovascular accident; ARF, acute renal failure; AKI, acute kidney injury; VSRR, valve-sparing root replacement.
| Variable | Data |
|---|---|
| Bleeding sitesa) | |
| General ooze from an unlocalized area | 14 (70.0) |
| Needle holes in the suture line | 8 (40.0) |
| Posterior to the anastomotic site | 3 (15.0) |
| Intraoperative transfusion (mL) | |
| pRBC | 1,120.0 (800.0–1,600.0) |
| Platelet concentrate | 640.0 (430.0–800.0) |
| FFP | 720.0 (360.0–1,215.0) |
| Cryoprecipitate | 320.0 (140.0–400.0) |
| Postoperative chest tube output (mL) | 1,352.5 (740.0–2,295.0) |
| Postoperative transfusion (mL) | |
| pRBC | 1,105.0 (445.0–1,537.5) |
| Platelet concentrate | 220.0 (0.0–442.5) |
| FFP | 550.0 (79.8–1,170.0) |
| Cryoprecipitate | 0.0 (0.0–180.0) |
| Cost (US$) | c-GSUC | VAC |
|---|---|---|
| Initial cost | 33.2 | 79.2 |
| Daily maintenance cost | 4.3 | 111.2 |
| Total theoretical cost | 6.3 (4.3–8.5) | 166.8 (111.2–222.4) |
| Variable | Data |
|---|---|
| Duration of stay (day) | |
| Intensive care unit | 6.0 (4.3–12.3) |
| Total hospital stay | 17.5 (13.5–27.3) |
| Death | 2 (10.0) |
| Other complications | |
| Cerebrovascular accident | 5 (25.0) |
| Pericardial effusion | 3 (15.0) |
| Pleural effusion | 2 (10.0) |
| Acute kidney injury | 5 (25.0) |
| Atrioventricular block | 1 (5.0) |
| Mediastinitis | 3 (15.0)a) |
| Wound dehiscence | 3 (15.0)a) |
| Pneumonia | 2 (10.0) |
| Sepsis | 2 (10.0) |
| No. | Age (yr) | Sex | OPs | Preoperative conditions | Previous OP (n) | Anticoagulation | PLT (×103/μL) | Hb (g/dL) | Hct (%) | aPTT (sec) | PT (INR) | OP time (min) | CPB time (min) | ACC time (min) | Postoperative chest output (mL) | ICU (day) | GW (day) | Complications |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 72 | M | AVR, MVR | IE (Elective) | 0 | Aspirin | 138 | 10.6 | 29.4 | 39.0 | 1.17 | 540 | 245 | 200 | 740 | 7 | 16 | None |
| 2 | 54 | M | MVR, Bentall | IE (Elective) | 2 | None | 270 | 11.2 | 33.2 | 39.0 | 1.19 | 585 | 320 | 300 | 2,430 | 10 | 35 | AV block |
| 3 | 46 | M | AVR, AscAoR, CABG | (Elective) | 0 | Aspirin + clopidogrel | 233 | 11.5 | 33.9 | 32.0 | 1.05 | 570 | 330 | 160 | 740 | 17 | 22 | CVA, pericardial effusion, ARF |
| 4 | 56 | F | AVR, TVP, AscAoR | (Elective) | 0 | None | 212 | 10.3 | 31.6 | 39.0 | 1.05 | 510 | 210 | 90 | 1,400 | 8 | 20 | CVA |
| 5 | 38 | M | MVR, TVP, CABG | Behcet (Elective) | 2 | Warfarin | 195 | 12.8 | 37.6 | 51.7 | 1.41 | 560 | 300 | 258 | 1,030 | 5 | 19 | None |
| 6 | 64 | F | AscAoR | (Emergency) | 1 | None | 120 | 14.2 | 42.7 | 36.4 | 1.22 | 520 | 220 | 137 | 2,300 | 6 | 11 | None |
| 7 | 47 | M | Bentall, CABG | Behcet (Elective) | 2 | Aspirin | 170 | 10.3 | 29.7 | 48.3 | 2.41 | 825 | 420 | 225 | 940 | 13 | 28 | None |
| 8 | 68 | M | Bentall, CABG | IE, mediastinitis (Elective) | 1 | None | 117 | 10.8 | 32.9 | 51.9 | 2.22 | 720 | 432 | 268 | 3,590 | 25 | 25 | Pericardial effusion, AKI, wound dehiscence, death |
| 9 | 76 | F | AscAoR, total arch | Emergency | 0 | None | 345 | 10.4 | 31.6 | 35.6 | 1.32 | 350 | 189 | 111 | 2,280 | 6 | 18 | Pleural effusion |
| 10 | 61 | M | Bentall | IE (Emergency) | 1 | Warfarin | 188 | 8.7 | 25.3 | 52.4 | 2.1 | 525 | 282 | 216 | 630 | 3 | 43 | None |
| 11 | 58 | F | AscAoR | (Emergency) | 0 | None | 70 | 13.2 | 42.9 | 31.1 | 1.02 | 360 | 136 | 76 | 760 | 3 | 12 | None |
| 12 | 53 | M | Bentall, AscAoR, Total arch | (Elective) | 1 | None | 126 | 10.1 | 30.9 | 34.6 | 1.13 | 460 | 218 | 137 | 1,305 | 3 | 13 | None |
| 13 | 56 | M | VSRR, AscAoR | Marfan (Emergency) | 0 | None | 234 | 13.4 | 40.3 | 48.0 | 1.13 | 420 | 221 | 196 | 2,050 | 5 | 17 | None |
| 14 | 50 | F | VSRR, AscAoR | (Emergency) | 0 | None | 236 | 13.9 | 42.6 | 33.7 | 1.02 | 340 | 213 | 164 | 680 | 2 | 9 | Pleural effusion |
| 15 | 70 | F | AVR, AscAoR | (Emergency) | 0 | None | 168 | 11.1 | 33.5 | 40.6 | 1.23 | 530 | 258 | 202 | 560 | 6 | 17 | Pericardial effusion |
| 16 | 44 | M | AscAoR, total arch, CABG | (Emergency) | 0 | None | 146 | 13.6 | 39.9 | 39.1 | 1.23 | 1,020 | 481 | 239 | 2,760 | 6 | 17 | AKI |
| 17 | 86 | M | Bentall | IE, (Elective) | 1 | Aspirin | 138 | 11.6 | 33.8 | 40.4 | 1.12 | 660 | 308 | 199 | 6,472 | 8 | 13 | AKI, mediastinitis, wound dehiscence, sepsis |
| 18 | 65 | M | Bentall | Behcet, mediastinitis, (Elective) | 2 | None | 291 | 9.8 | 28.9 | 51.5 | 1.33 | 780 | 344 | 242 | 2,062 | 21 | 41 | Wound dehiscence |
| 19 | 64 | M | AscAoR, total arch | (Emergency) | 0 | None | 105 | 15.9 | 47.3 | 44.2 | 1.7 | 470 | 240 | 165 | 1,610 | 47 | 53 | CVA, AKI, pneumonia, death |
| 20 | 42 | M | MVR, VSRR, AscAoR | Marfan (Elective) | 0 | None | 159 | 9.1 | 26.6 | 30.0 | 0.97 | 660 | 260 | 234 | 660 | 4 | 15 | CVA |
| Characteristic | Data |
|---|---|
| Demographics | |
| No. of patients | 20 |
| Age (yr) | 57.0 (47.8–67.3) |
| Male sex | 14 (70.0) |
| Anticoagulation | |
| Aspirin | 4 (20.0) |
| Clopidogrel | 1 (5.0) |
| Warfarin | 2 (10.0) |
| Clinical condition at the time of surgery | |
| No. of previous surgeries via sternotomy | |
| 0 | 11 (55.0) |
| 1 | 5 (25.0) |
| 2 | 4 (20.0) |
| Infective endocarditis | 5 (25.0) |
| Connective tissue disease | 5 (25.0) |
| Preoperative laboratory findings | |
| Platelet counts (×103/µL) | 169.0 (129.0–233.8) |
| Hemoglobin (g/dL) | 11.5 (10.0–13.8) |
| Hematocrit (%) | 33.5 (30.3–40.0) |
| WBC count (/μL) | 8,515.0 (6,722.5–13,297.5) |
| aPTT (sec) | 39.0 (35.3–48.0) |
| PT (INR) | 1.0 (1.0–1.0) |
| Variable | Data |
|---|---|
| Indexed procedure, CABG | 4 (20.0) |
| Valve operation | |
| Aortic | 14 (70.0) |
| Mitral | 4 (20.0) |
| Tricuspid | 2 (10.0) |
| Aortic surgery | 19 (95.0) |
| Perfusion details, min | |
| Operation time | 535.0 (462.5–660.0) |
| CPB time | 259.0 (218.5–327.5) |
| ACC time | 199.5 (142.8–237.8) |
| Duration of open chest management, day | 1.5 (1.0–2.0) |
| 1 | 10 (50.0) |
| 2 | 8 (40.0) |
| 3 | 2 (10.0) |
| Chest closure location | |
| Operating room | 18 (90.0) |
| Intensive care unit | 2 (10.0) |
| Variable | Data |
|---|---|
| Bleeding sites |
|
| General ooze from an unlocalized area | 14 (70.0) |
| Needle holes in the suture line | 8 (40.0) |
| Posterior to the anastomotic site | 3 (15.0) |
| Intraoperative transfusion (mL) | |
| pRBC | 1,120.0 (800.0–1,600.0) |
| Platelet concentrate | 640.0 (430.0–800.0) |
| FFP | 720.0 (360.0–1,215.0) |
| Cryoprecipitate | 320.0 (140.0–400.0) |
| Postoperative chest tube output (mL) | 1,352.5 (740.0–2,295.0) |
| Postoperative transfusion (mL) | |
| pRBC | 1,105.0 (445.0–1,537.5) |
| Platelet concentrate | 220.0 (0.0–442.5) |
| FFP | 550.0 (79.8–1,170.0) |
| Cryoprecipitate | 0.0 (0.0–180.0) |
| Cost (US$) | c-GSUC | VAC |
|---|---|---|
| Initial cost | 33.2 | 79.2 |
| Daily maintenance cost | 4.3 | 111.2 |
| Total theoretical cost | 6.3 (4.3–8.5) | 166.8 (111.2–222.4) |
| Variable | Data |
|---|---|
| Duration of stay (day) | |
| Intensive care unit | 6.0 (4.3–12.3) |
| Total hospital stay | 17.5 (13.5–27.3) |
| Death | 2 (10.0) |
| Other complications | |
| Cerebrovascular accident | 5 (25.0) |
| Pericardial effusion | 3 (15.0) |
| Pleural effusion | 2 (10.0) |
| Acute kidney injury | 5 (25.0) |
| Atrioventricular block | 1 (5.0) |
| Mediastinitis | 3 (15.0) |
| Wound dehiscence | 3 (15.0) |
| Pneumonia | 2 (10.0) |
| Sepsis | 2 (10.0) |
M, male; F, female; OP, operation; PLT, platelet count; Hb, hemoglobin; Hct, hematocrit; aPTT, activated partial thromboplastin time; PT, prothrombin time; INR, international normalized ratio; CPB, cardiopulmonary bypass; ACC, aortic cross-clamp; ICU, intensive care unit; GW, general ward; AVR, aortic valve replacement; MVR, mitral valve replacement; IE, infective endocarditis; AV block, atrioventricular block; AscAoR, ascending aorta replacement; CABG, coronary artery bypass grafting; TVP, tricuspid valvuloplasty; CVA, cerebrovascular accident; ARF, acute renal failure; AKI, acute kidney injury; VSRR, valve-sparing root replacement.
Values are presented as number, median (interquartile range), or number (%). WBC, white blood cell; aPTT, activated partial thromboplastin time; PT, prothrombin time.
Values are presented as number (%) or median (interquartile range). CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass; ACC, aortic cross-clamp.
Values are presented as median (interquartile range) or number (%). pRBC, packed red blood cells; FFP, fresh frozen plasma. Bleeding focus can overlap in incidence.
Values are presented as cost or median (interquartile range). c-GSUC, chest-gauze suction; VAC, vacuum-assisted closure; IQR, interquartile range.
Values are presented as median (interquartile range) or number (%). Two patients with mediastinitis and wound dehiscence at the time of surgery were transferred to our institution.